期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

分子靶向治疗药物引起造口周围痤疮样皮疹的护理

原文传递
导出
摘要 分子靶向治疗是以肿瘤细胞过度表达的某些标志性分子为靶点，选择针对性的阻断剂，有效干预受该标志性分子调控及密切相关的信号传导通路，从而抑制肿瘤生长、进展及转移。相对于传统的手术、放疗、化疗三大治疗手段，
作者 徐洪莲 傅传刚
机构地区 第二军医大学附属长海医院肛肠外科
出处 《中华结直肠疾病电子杂志》 2013年第2期34-35,共2页 Chinese Journal of Colorectal Diseases(Electronic Edition)
关键词 分子靶向治疗药物 痤疮样皮疹 护理 周围 造口 信号传导通路 抑制肿瘤生长 过度表达
分类号 R473.73 [医药卫生—护理学]
  • 相关文献

参考文献6

二级参考文献37

  • 1徐洪莲,王汉涛.造口周围粪性皮肤炎的治疗[J].中国普外基础与临床杂志,2005,12(1):13-14. 被引量：42
  • 2Huang SM,Bock JM, Harari RM. Epidermal growth factor receptor blockade C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck[J]. Cancer Res, 1999,59(8) : 1935-1940.
  • 3Ciardiello F,Damiano V,B ianco R,et al. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A [J]. J Natl Cancer Inst, 1996, 88 (23) : 1770- 1776.
  • 4Huang SM, Li J, Harari PM. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade[J]. Molecular Cancer Therapeutics, 2002,1 (7) : 507-514.
  • 5Y Abubakr, C Eng, V Pautret, et al. Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC) : Safety analysis of 800 patients in a randomized phase Ⅲ trial (EPIC)[J]. Prec Am Soc Clin Oncol, 2006,24 (18S) : 3556.
  • 6Scartozzi M,Bearzi I, Berardi R, et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies[J]. J Clin Oncol,2004,22(23) :4772-4778.
  • 7Italiano A, Foliana P, Caroli FX,et al. Cetuximab shows activity in eolorectal cancer patients with tumors for which F1SH analysis does not detect an increase in EGFR gene copy number[J]. Ann Surg Oncol, 2008,15(2) :649-654.
  • 8E Van Cutsem, I Lang, G D'haens,et al. KRAS status and efficacy in the first-line treatment of patients with metastatic eolorectal cancer (mCRC) treated with FOLFIRI with or with out cetuximab: The CRYSTAL experience[J]. Prec Am Soc Clin Oncol, 2008,2.
  • 9Tejpar S, Peeters M, Humblet Y, et al. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (qlw): The EVEREST experience (preliminary data)[J]. Prec Am Soc Clin Oncol, 2008,4001.
  • 10Hans W. Retracted stomas and the optimization of convex ostomy products [ J ].WECT, 2004,24 (3) :26-28.

共引文献107

中华结直肠疾病电子杂志
2013年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部